A

n experimental gene therapy that turns a patient’s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday.

In all, 82 percent of patients had their cancer shrink at least by half at some point in the study.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Good news. I am 9 months cancer free after participating in the Juno CAR 17 trial for relapsed NHL. My chemo induced peripheral neuropathy has gotten much worse. Do you have any evidence from Kite relative to patients who started their trial with my problem and how their CIPN has been affected. I can not get any response from Juno when I tell City of Hope how bad my pain and leg and hand cramping has become. Keep the info coming. I talk to lots of patients at COH who have no idea these clinical trials are out there. Steve Kohn-San Diego

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.